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Introduction
The Tenth Scientific Congress of the Polish Society of Nuclear
Medicine was held on 22nd24th June, 2006 in Bialystok, the cap-
ital of the beautiful Polish Eastern Frontiers  a country of vast
plains, open people, zubrovka grass and the famous Bialowieza
Wild Forest. It is my pleasure to summarise the Congress, but
please forgive my criticisms here and there and/or some nostal-
gic/sad remarks, also please forgive my omitting some Congress
presentations, there were so many of them.
The Congress comprised 12 programme lectures (including
7 by eminent foreign scholars), 54 oral presentations, 66 poster
presentations and a vast social programme. All of this was thanks
to the organiser; the indefatigable, incredible and magnificent Pro-
fessor Franciszek Rogowski.
Neurology
From congress to congress, more and more presentations
are devoted to neurology; today the main NM neurological centre
in Poland seems to be £ód.
Image fusion: a solid paper by Górska-Chrz„stek et al., i.e.
a song about how nice is to have SPECT/CT; from the same
centre a nice paper on methyltyrosine in brain tumours, a theme
both old and new, important because of more and more visible failu-
res of PET in some brain tumours. Also from the same centre there
was a presentation on rCBF brain SPECT in systemic lupus erythe-
matosus. The results, as usual in that field, were broad, but not al-
ways conclusive. I wrote some papers about it. Its a difficult job
The problem of brain tumours was also raised by Jakuciæski
et al., Medical University, Warsaw, stating the occurrence of so-
matostatin receptors in 75% of brain tumour patients; showing
this to be weak as a diagnostic test, but fairly promising as an
introduction to peptide therapy, and, in fact, the next paper by
the same authors discusses the results of Y-90-DOTA-TATE ther-
apy in patients with inoperable brain tumours, with very promis-
ing results.
From the once renowned Gdaæsk NM neurological centre there
was only one paper by Piskunowicz et al., which was interesting in
that it raised the criminal aspects of rCBF SPECT brain scanning,
i.e. the application of this technique in forensic medicine, this is
a nice niche problem, please continue.
The Military Medical Institute in Warsaw (Bilski et al) is proud
to possess the BRASS computer programme and voxel based
analysis. Today neurological nuclear medicine is hardly possible
without 3D analysis.
Cardiology
The presentations concentrated on different means of RI cor-
onary disease analysis. Teresiæska et al. from the Institute of Car-
diology, Warsaw, assessed heart muscle imminent necrosis
using GSPECT and the efficacy of treatment with stent implantation
and thrombectomy, the latter was found to be superior. Wnuk,
Chojnowska et al from the same centre assessed the efficacy of
therapeutic angiogenesis using RI techniques, stating the improve-
ment of EF. Congratulations!
Czepczyæski et al. (Medical University, Poznaæ) worked with
the myocardial infarct therapy by the transplantation of bone mar-
row cells; I am not sure whether I would back administering pla-
cebos in experiments of that kind. Miko, Dziuk et al. (Warsaw)
raised an important question concerning the complementary (or
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competitive?) role of SPECT scanning and MRI-gadolinium-en-
hanced scanning. Radiology attacking, SPECT defending its role,
image fusion raises the diagnostic effect very well.
MIBI-SPECT in heart transplant, from Warsaw Cardiology In-
stitute, gave interesting results  lots of perfusion disturbances,
mostly diffused ones, sometimes with high progression, showing
it to play an important role in the diagnostic algorithm of those
patients. Bia‡ystok NM centre  Parfieæczyk, Rogowski et al., our
kind hosts, studied heart perfusion in systemic sclerosis with some
peculiarities both in stress scanning and e.g. inversely improved
perfusion at rest in some cases; thats interesting  in vasculitis
paradoxical vascular reactivity is quite frequent, I showed it my-
self some time ago in cerebral circulation.
Pietrzykowski et al. (Warsaw) analysed the influence of heart
arrhythmias and heart size on GSPECT results; in a large cohort
they found lower EF fraction, which could be expected, but
 what is interesting  EF may be artificially high at low end-
-systolic and end-diastolic volumes. Szczepaæski, Teresiæska et
al. (Warsaw) compared the results of heart perfusion scanning
utilising two different ways of polar map segmentation: a lower
amount of segments in the polar map was shown to decrease the
parameters of summarized perfusion deficit (SDS). Szumiæski,
P‡achciæska et al. analysed how the supplementation of myocar-
dial scintigraphy with assessment of contractility improved the
efficiency of scanning; in fact, so it went significantly, strangely,
the authors criticized the CEqual computer programme so highly
advocated by the producer.
Cardiology  risk stratification
Dziuk, Kamierczak et al. (Military Medical Institute, Warsaw)
assessed the prognostic value of stress heart perfusion scanning
in a large group of 174 patients; the strongest prognostic para-
meter was the positive result of scanning, and its depth; negative
results indicated a low probability of grave cardiac events (< 1%
per year). Those results are important, as they can help to pro-
mote radionuclide techniques among the cardiologists. Another
presentation from the same centre analysed the risk of cardiovas-
cular events in non-smoking patients younger that 60 years old
with lipid disturbances.
Endocrinology
As usual, the most interesting papers were from Poznaæ Uni-
versity: two fascinating  papers by Kosowicz, Czepczyæski et al.
on medullary carcinoma; one on gastrin receptors, and the sec-
ond comparing (V)DMSA and HYNIC-TOC, both with very high
efficacy. Medullary carcinoma and its metastases scanned with
I-131-MIBG were studied by £apiæska et al. (Institute of Oncolo-
gy, Warsaw). They had interesting results and nice images, but it
is slightly unclear what the reference group was. Two papers from
Bia‡ystok were devoted to apoptosis; the first one on apoptosis
markers after rhTSH and radioiodine therapy, and the second on
the correlation of MIBI scanning, hormonal function and apoptot-
ic index  could this be the solution to hypothyreosis prognosti-
cation? A very interesting paper from Szczecin was presented by
Listewnik, Birkenfeld et al. on ophthalmopathy following radioiod-
ine therapy. They screened files of 4059 patients and found
9 patients with ophthalmopathy following RIT, thus leaving more
answers than questions, but its very good that someone is  wor-
king with that issue. Carry on.
Endocrinology  NET
An interesting presentation was presented by Jurecka et al.
from the Institute of Oncology in Gliwice. They underlined the im-
portance of strict inclusion criteria to RI NET treatment, otherwise
it makes little sense in this difficult and costly treatment.
Another interesting paper was presented by Hubalewska et
al. from Cracow on intra-operation gamma probe in the surgery of
carcinoids and insulinomas, with very good results. From the same
centre there was a comparison of CT, MRI an RI studies in NETs
of the pancreas (22 cases). The authors say that if scintigraphy is
positive, we can operate CT, and MRI has a secondary meaning.
Perhaps they are too much in love with their methodbut if they
are right? They can be.
NETs  technical remarks; Lenda-Tracz et al. (Cracow) com-
pared the results of FBP and iterative (OSEM) SPECT recon-
struction modes; OSEM is better than ITW. It was proven in the
brain and heart, but in neuroendocrine tumours it is probably
new. Congratulations! Its a pity that the material is rather small
(14 cases). Szalu et al. (MMI, Warsaw) analysed the utility of RI/CT
image fusion in predicting response to radioisotope therapy;  pilot
results were very promising, lets wait for more than 4 studied
patients.
Depreotide in hypophysis tumours as a specific imaging agent,
discriminating other imaging modalities  thats the opinion of
Nocuæ et al. from Lublin. OK  this could be interesting. How-
ever, what would be the place of this costly imaging in the clinical
algorithm? What do the neurosurgeons think?
Warsaw Medical University NM centre is faithful to parathyroid
imaging. Kobylecka et al. presented three nice papers on it, al-
though the aim of the third one (testing the utility of intra-operation
hand-held gamma probe scanning in tumour differentiation)
is perhaps too ambitious. However, this or that way, gamma probe
scanning gives the best practical results.
Oncology
Oncology  sentinel node
Czepczyæski et al. from Poznaæ showed an interesting series of
19 ENT tumour patients with well-documented efficacy. In more
conventional sentinel node RI localisation JŒdrzejczak et al from the
Institute of Oncology (Warsaw) presented a well-documented series
of 286 patients with breast cancer, although with rather static results.
Another paper on the same subject from Wroc‡aw showed
very good sensitivity of gammacamera scanning of sentinel nodes
 93%. I wish I could achieve the same sensitivity, but I do believe
in hand-held gamma probe SN finding. A similar large series of SN
findings by Birkenfeld et al. on 118 melanoma cases by Birkenfeld
et al. from Szczecin, gave solid performance, nice results, although
I do not fully understand the sense of detecting the sentinel node in
upper and lower extremities melanoma cases.
Oncology  peptides
Noble self-criticism was the dominating feature of the presen-
tation on depreotide vs. EDDA/HYNIC-TO given by P‡achciæska,
Miko‡ajczak et al (£ód/wierk); the results are usually the best of
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the authors, but here the authors criticized their own results; both
tracer scannings, depreotide scanning had better count statis-
tics, false-positive rate was high in mediastinum and hilar region.
JŒdrzejczak et al. from IO, Warsaw studied the usefulness of dep-
reotide in pulmonary opacities of unknown origin, if the sensitivity
is 95%, specificity 82%; if they are right, PET could be forgotten.
Really? Unconventional depreotide application in sarcoidosis by
Pilecki et al. from Bydgoszcz, in 5 patients some promising re-
sults. Its worthy carrying on.
Oncology  varia
Scintimammography  a slightly outdated topic, one might think
 and here a nice presentation on the usefulness in prognostication
of treatment efficacy by Listewnik, Birkenfeld et al. Interesting.
Further in the mainstream of therapeutic applications: Sowa-
-Staszczak et al. (Cracow) said that Y-90-Zevalin had consolidated
and stimulated the effect of chemotherapy, although the results
were quite dispersed (sometimes it worked, sometimes not) and
described (at least in the summary) in a style of s.c. hermetic prose.
Image fusion
Image fusion is a very important thing and a second breath
for nuclear medicine  if we cannot beat CT/MRI with spatial re-
solution, lets join them.
DAmico et al. from Gliwice fused SPECT and 16-row CT
images, good job, they say that manually established points of
fusion will serve the SPECT/CT Hawkeye device (is the CT part of
it so good?). 76 patients, quite a lot, very nice results in abdomi-
nal imaging and in gliomas.
There were three nice papers on PET/CT from the Oncologi-
cal Centre in Bydgoszcz. The first presentation was about natri-
um-18F-fluoride in detecting bone metastases, PET/CT 3 times
better than MDP scanning. Really? The second paper was about
126 patients with ovarian carcinoma, 98% sensitivity and 98%
specificity. And a third, perhaps the most interesting in that se-
ries, was about PET/CT on neoplasms with unknown sites of ori-
gin, sensitivity 55%, which is a good result, regarding known dia-
gnostic difficulties in that group of pathology.
Zuchora et al., from the same centre, presented a paper on
PET/CT in brain tumour recurrence; interesting speech, as that
aspect of PET scanning is still a matter of controversy, some be-
lieve that gadolinium-enhanced MRI is better, the authors defend-
ed PET like lions. The same centre and PET/SPECT in craniofacial
tumours  interesting, somewhat small subgroups, but it is worth
carrying on.
PET
Unavoidable neuroendocrine tumours (NET)  I have the
impression that anybody who does not publish about them today
is passŁ i demodŁ. Ma‡kowski, Walecki and ˘wik‡a (Warsaw) as-
sessed highly malignant NETs with vaguely convincing PET re-
sults when compared to somatostatin on receptor scanning (SRS).
PET/CT in radiotherapy planning; this was a presentation by
Kobus-B‡achnio et al. from Bydgoszcz  in patients with NSCLC,
PET/CT caused rearrangement of irradiation areas in half of the
patients. Very practical.
Paediatrics
Cholestasis in neonates; a group of Kamiæska et al. from the
Centre of Childrens Health (CZD), Warsaw praised the superio-
rity of cholescintigraphy with extraction fraction  (HEF), over a sen-
sitive but not very specific ultrasound examination.
Similarly hepatic clearances were advocated by Surma from
£ód, probably the leading expert in that field in Poland, who has
been faithful to the subject for ages.
Again CZD; an interesting paper on cholescintigraphy in ex-
trahepatic biliary tree cysts; a rare disease, therefore gathering an
ample material of 68 patients is a good thing, but results could be
more convincing (what were the results of reference methods?),
perhaps comparing the image pre- and post-operation would
make sense.
Changes of lung perfusion following Fallot tetralogy opera-
tions were shown by Romanowicz et al. from Gdaæsk in a solid
cohort of 110 patients, 60% of perfusion asymmetries, 40% of
regional perfusion deficits, thats interesting, but what becomes
of it in practice?
A nice paper on nephrotoxicity in leukaemia chemotherapy
was given by Matacz, Zorga et al. A large group of patients with
recommendation of dynamic renal scanning before and after che-
motherapy; really? Chemotherapy slightly alters the morphology
of kidneys, true, but what later? Too little for stable placement of
this technique of the diagnostic algorithm. The group of Zawilak
et al from £ód presented small local areas of decreased clear-
ance renal function in diabetes. Interesting  kidneys lesioned
piece by piece?
From the same centre, the next diabetological paper by
Frieske, Kumierek et al., who analysed, with very impressive
precision of statistical analysis, the usefulness of dynamic kid-
ney scanning in the early stages of diabetic nephropathy, sta-
ting regional perfusion defects and the usefulness of parametric
imaging, even at normal global parameters of kidney function.
Important.
An interesting paper was presented by Kostkiewicz et al. from
Cracow on the simple but practical problem of renal function pre-
and post-renal angioplasties. Lots of interesting results. However,
the observation period of 3 months seems to be too short,
although in 2 patients re-stenosis has been shown already, after
such a short period.
Radionuclide therapy
Peptides
As expected, lots of papers on DOTATATE with yttrium-90,
peptides still on the top. Handkiewicz et al applied such therapy
in 11 patients with NETs, remission in two, no progression in the
rest: so far, so good. Another paper from Warsaw by ˘wik‡a et al.
 19 patients, with good visualisation of metastases resulting
from brehmsstrahlung.
Bones
Strontium-89 and samarium-153, a comparison of treatment
in prostate and breast carcinoma  solid material of 60 patients
by B„czyk et al. from Poznaæ. In conclusion, samarium is better in
osteolytic and mixed metastases, especially when bisphospho-
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nates were added, a slightly static presentation, but an important
vocal discussion on that type of treatment.
Thyroid
Thyroid, after 60 years of presence in nuclear medicine, is still
a mysterious organ  that is the reason why I like it, we can speak
about it again and again.
Kijek et al. (Lublin) precisely compared the results of treat-
ment of hyperthyreosis and metabolism of I-131; radioiodine up-
take and effective half decay with no influence in Graves disease
treatment  do we come back to the fixed dose treatment?
From the same centre: after the treatment, Trab and anti-TPO
antibodies levels up? Already heard, I believe.
Radioiodine in subclinical hyperthyreosis  a problem raised
by Abdelrazek et al. (Bia‡ystok). That is important, euthyreosis in
99%, although an observation time of one year is slightly too short.
Factors influencing hypothyreosis occurrence following toxic
adenoma radioiodine treatment, by Listewnik et al., Szczecin,
a solid meta-analysis, ho ho! They mixed and compared every-
thing with everything, a very hard statistical work, as the main
markers of the above seem adenomas volume and radioiodine
24 hrs uptake.
Returning to the beautiful county of Bialystok, i.e. the realm of
apoptosis. Sopotyk et al. indefatigably studied the level of  pro-
and anti-apoptotic markers, assuming that late hypothyreosis is
a result of excessive apoptosis stimulation, with somewhat few con-
clusive results, perhaps it will be better with annexin-V imaging.
An interesting paper from Lublin. Stefaniak et al. applied neu-
ral networks in prognostication of radioiodine in toxic adenoma
radioiodine treatment. Neural networks, i.e. the device (potential-
ly) replacing the mind of a medical doctor, is a very trendy topic,
at least at present. The authors show a very high utility of it in
predicting efficacy, with some risk of falsely positive predictions.
Lublin centre also gained great expertise in neural networks in
other applications, its worth keeping an eye on their progress.
A very interesting paper was presented by P‡aziæska et al. from
Warsaw on radioiodine therapy in haemodialysed patients. Sim-
ple, but nice. Retention of radioiodine is of course prolonged, and
TEff highly dispersed, therefore administered radioiodine activi-
ties should be tailored to renal function parameters.
Thyroid carcinoma
Mediastinal radioiodine accumulation  the group Pisarska
et al. from Kielce went through this problem in a very thorough
way using a vast amount of material from 2000 patients, postulat-
ing an increase in administered radioiodine activity and applying
the semiquantitative analysis of mediastinal uptake, as 1/3 of
mediastinal metastases escape conventional scintigraphic radio-
iodine detection. Interesting and of practical value.
From the same centre: whole body radioiodine scintigraphy
in multiple metastases of differentiated thyroid cancer, 455 pa-
tients; in lung metastases sensitivity 53%, specificity 100%, in
bones 100% of both. Have I already heard this before?
Poznaæ centre, Macioszek et al studied the nonspecific I-131
accumulation in radioiodine whole-body scanning; delayed
image acquisition doesnt help much, a very practical study.
Poznaæ again  B„czyk et al. are proud, and so they should
be, of their results of radioiodine thyroid cancer treatment in
a group of 1115 patients; perfectly detailed analysis, interesting
three-fold increase of differentiated thyroid carcinoma detection
in Poznan District in the last two decades.
Radiosynoviorthesis
A comparison of three methods: surgery, arthroscopic inter-
vention and radiosynoviorthesis by the Gdynia group (£uka et al.);
in all three modalities equally good effects in a sound group of
300 patients with knee effusion  therefore, like in the famous
meta-analysis on sentinel nodes by Paganelli why pay more to
gain the same, a solid voice advocating radiosynoviorthesis, pure
and simple.
Inserting some general remarks: radiosynoviorthesis is one of
the more pleasant adventures of Polish nuclear medicine in re-
cent years - better late than never, stable methods, real gains for
patients and the development of Polish NM.
The next three papers were on the same topic, from Bia‡ystok
(Parfieæczyk et al.), Gdaæsk (Romanowicz et al.) and Lublin  (Chrap-
ko et al.), the results were similar everywhere, the Lublin team
were a bit more precise, in the Gdaæsk paper there was correla-
tion with knee joint ultrasound examinations, but few conclusions,
after all. However, it is very nice that after years of stagnation in
that field we can chase the international NM community.
Radiopharmacy and radioprotection
188-Re-HEDP; Korsak et al. did a sound job, but  sorry
 rather an old topic? A presentation by Pawlak et al. on lute-
tium-177-EDTMP synthesis; they gained a high stability and ra-
diochemical purity, but  excuse me  that lutetium-177 is
somehow unlucky. Works on it last for years, but somehow can-
not successfully compete with the saintly couple, strontium-89
 samarium-153.
We have the same problem with rhenium-188; its generator
produced by wierk centre, nice paper by fluchliæska et al., and
little makes little, clinical utilisation is progressing very slowly. By
the way, the same problem is shared by metastable tin-117, phos-
phorus-33 and some others.  Improvements in iodine-123 pro-
duction by Bartyzel et al. from Cracow  important.
Radiopharmaceutical papers would be incomplete without the
paper platinium (IV) complex with [*I] histamine as a radiophar-
maceutical in radio-chemotherapy of neoplasms, modification of
its structure improves biodistribution. The indefatigable group of
Maurin and Garnuszek have been polishing that subject for years
and I admire their faith to the idea.
Yttrium-90 and lutetium-177 as therapeutic agents  peptide
labelling by Pawlak, Miko‡ajczak et al., standards good as gold,
this is very important not only in the context of common NET-
-mania, but also for other therapeutic goals. Congratulations!
The possibilities of whole body scintigraphy in patients with
administered beta-emitting radionuclides was presented with
yttrium-90 as an example by Bajera from Warsaw  pure, simple
and important. The author proves that brehmsstrahlung by Y-90
enables image registration, very important for dosimetry.
Radioprotection of patients and staff in radiopeptide therapy
 the paper by Bilski et al from Military Medical Institute, Warsaw
 is very important, when almost everybody in Polish NM wants
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to do it. Speedy elimination with urine (75% of activity excreted
within first 6 hrs post-injection); their postulate of building reten-
tion tanks everywhere, when radiopeptide therapy is applied is
a) disputable; b) to be proven by stronger evidence.
Varia
OBRI/POLATOM with a paper on ophthalmic applicators of
 106-Ru and 125-I and 125-I in oncological brachytherapy, nice
 I like OBRI!, laborious folks  but it is rather the domain of
radiotherapy, not NM. Oczeretko et al. (Bia‡ystok) faithful for ages
to Falk image analysis, which is nice. An interesting paper from
Lublin by Stefaniak et al. on a phantom for simulated brain SPECT
analysis; hard and solid job, unexpectedly better results in FBP
than ITW image reconstruction. Its good that such a paper has
been presented, its a shame that only two groups in Poland
 Lublin team + Bandurski & wietlik in Gdaæsk  work in the
frontier of nuclear medicine and computer sciences.
Concluding remarks, i.e. good and bad news
Good news
Good news  things are getting better! The author of this
presentation has witnessed the Polish Nuclear Medicine Society
Congresses since their beginning, i.e. almost 20 years ago,
and, by Jove, its better in two/three areas! e.g. in NETs and
radiopharmacy, the quality of papers is definitely better, quite
a lot PET papers; some promising flashes in RN coronary dis-
ease studies, but...
Bad news
We are not only losing contact with top world nuclear medi-
cine; I believe we, as a community have already lost it! For some
time, in niche areas, a good concept, daring thought and labo-
riousness were good enough  today this is no longer true. This
was proven by the recent 2005 Constantinople EANM Congress
or the lectures of any issue of EJNM&MI. 75% of papers either on
PET or the new tracers, the names of which sound like science
fiction movies to our ears; PET presentations are in the poster
sessions, and we can only dream about new software  like HER-
MES on NM image analysis, for financial reasons.
We are chasing  with little effect  not only the world nucle-
ar medicine community, but the Polish NM community looses when
compared even with our neighbours, I am speaking not only about
Germany (2.800 gamma-cameras, 80 PET units), I am speaking
also about the Czech Republic (1.5 × higher Gross National Pro-
duct, but 6% of it given to health care, not 3.6% as in Poland), I am
speaking about Hungary, where quantity goes into quality. In Po-
land the simple reserves in NM are finished, therefore, in the
amount of presentation in EANM congresses, we are lower.
Concluding remarks, i.e. how to survive,
when no miracles exist
Lets work together, ladies and gentlemen. Our chance is
multicentric cooperation, which has succeeded in NETs, also
something which largely disappeared in comparison with previous
Polish SNM congresses i.e. papers ensuing from international
cooperation.
